Consainsights logo
Reports > Life Sciences > Influenza Diagnostics Market Report

Influenza Diagnostics Market Size, Share, Industry Trends and Forecast to 2033

This report covers a comprehensive analysis of the Influenza Diagnostics market, including key insights, market trends, and forecasts from 2023 to 2033. It presents data on market size, regional dynamics, technology innovations, and industry leaders driving future growth.

Metric Value
Study Period 2023 - 2033
2023 Market Size $6.50 Billion
CAGR (2023-2033) 7.2%
2033 Market Size $13.29 Billion
Top Companies Abbott Laboratories, Roche Diagnostics, Cepheid, Becton, Dickinson and Company, Thermo Fisher Scientific
Last Modified Date 15 Nov 2024

Influenza Diagnostics Market Report (2023 - 2033)

Influenza Diagnostics Market Overview

The Influenza Diagnostics industry is characterized by a highly competitive landscape with significant investments in research and development. The growing emphasis on early diagnosis to mitigate the effects of influenza outbreaks has engendered a surge in demand for sophisticated diagnostic tools such as rapid antigen tests, molecular diagnostic techniques, and point-of-care testing solutions. Major healthcare institutions and diagnostics laboratories are increasingly adopting innovative technologies, thereby enhancing diagnostic accuracy and turnaround times. The market's robust growth trajectory is also spurred by supportive government initiatives aimed at combating influenza and promoting effective health management strategies.

What is the Market Size & CAGR of Influenza Diagnostics market in 2023?

In 2023, the Influenza Diagnostics market is projected to reach approximately $6.5 billion. Looking ahead, the market is expected to grow at a compound annual growth rate (CAGR) of 8.36% from 2023 to 2033, which will further elevate it to $14.8 billion by 2033. This growth can be attributed to the increasing incidence of influenza worldwide, ongoing technological advancements in diagnostic procedures, and a rising emphasis on preventive healthcare measures, fostering greater demand for innovative diagnostic solutions.

Influenza Diagnostics Industry Analysis

The Influenza Diagnostics industry is characterized by a highly competitive landscape with significant investments in research and development. The growing emphasis on early diagnosis to mitigate the effects of influenza outbreaks has engendered a surge in demand for sophisticated diagnostic tools such as rapid antigen tests, molecular diagnostic techniques, and point-of-care testing solutions. Major healthcare institutions and diagnostics laboratories are increasingly adopting innovative technologies, thereby enhancing diagnostic accuracy and turnaround times. The market's robust growth trajectory is also spurred by supportive government initiatives aimed at combating influenza and promoting effective health management strategies.

Influenza Diagnostics Market Segmentation and Scope

The Influenza Diagnostics market is segmented based on test methods, target viruses, technology, and end-users. Key segments include Molecular Diagnostics, Non-Molecular Diagnostics, Rapid Tests, and Laboratory Tests. Each segment plays a critical role in addressing various diagnostic needs, with molecular diagnostics commanding a significant market share due to their accuracy and reliability. The scope of the market extends across hospitals, diagnostic laboratories, and point-of-care settings, underscoring the diverse applications of influenza diagnostics in treatment and prevention efforts.

Request a custom research report for industry.

Influenza Diagnostics Market Analysis Report by Region

Europe Influenza Diagnostics Market Report:

In Europe, the market size is expected to start at $1.96 billion in 2023 and double to $4.01 billion by 2033. Increasing incidences of influenza and initiatives to improve diagnostic practices are significant contributors.

Asia Pacific Influenza Diagnostics Market Report:

In 2023, the Influenza Diagnostics market in the Asia Pacific region is estimated at $1.22 billion, with expectations to grow to $2.49 billion by 2033. The market is driven by increasing healthcare investments, rising awareness regarding influenza screening, and technological enhancements in diagnosis.

North America Influenza Diagnostics Market Report:

North America will dominate the Influenza Diagnostics market with a size of $2.40 billion in 2023, growing to $4.91 billion by 2033. The growth is supported by robust healthcare infrastructure, advanced diagnostics capabilities, and heightened awareness of public health.

South America Influenza Diagnostics Market Report:

The South American Influenza Diagnostics market is projected to reach $0.34 billion in 2023, with growth to $0.70 billion anticipated by 2033. Key factors include improving access to healthcare services and an uptick in diagnostic testing adoption.

Middle East & Africa Influenza Diagnostics Market Report:

The market in the Middle East and Africa is projected at $0.58 billion in 2023, with a growth forecast to $1.18 billion by 2033. Increased health investments and awareness about influenza's impact are driving growth in this region.

Request a custom research report for industry.

Influenza Diagnostics Market Analysis By Test Method

Global Influenza Diagnostics Market, By Test Method Market Analysis (2023 - 2033)

The market is greatly influenced by demographics in healthcare settings. Hospitals lead with a market size of $4.13 billion in 2023, expected to reach $8.43 billion by 2033, retaining a 63.48% market share. Diagnostic laboratories follow with $1.72 billion in 2023 and $3.51 billion by 2033, accounting for 26.43%. Point-of-care settings are gaining traction as rapid testing becomes increasingly vital, forecasting $0.66 billion growth to $1.34 billion by 2033.

Influenza Diagnostics Market Analysis By Target Virus

Global Influenza Diagnostics Market, By Target Virus Market Analysis (2023 - 2033)

Molecular diagnostics dominate the market with a size of $5.39 billion in 2023 projected to rise to $11.02 billion by 2033, holding an impressive 82.92% share. Non-molecular diagnostics are gaining ground, with a forecast from $1.11 billion in 2023 to $2.27 billion by 2033, representing 17.08%.

Influenza Diagnostics Market Analysis By Technology

Global Influenza Diagnostics Market, By Technology Market Analysis (2023 - 2033)

The market shows considerable reliance on rapid tests which account for $5.39 billion in 2023 and are expected to reach $11.02 billion by 2033 with an 82.92% market share. Laboratory tests represent a significant segment as well with growth projections reflecting the need for comprehensive diagnostic strategies.

Influenza Diagnostics Market Analysis By End User

Global Influenza Diagnostics Market, By End-User Market Analysis (2023 - 2033)

Hospitals are the leading end-users of influenza diagnostics, solidifying their essential role in managing influenza outbreaks. With a market share of 63.48%, hospitals are projected to sustain the largest sector share through 2033, contrasted by diagnostic laboratories and point-of-care settings that cater to diversifying healthcare needs.

Influenza Diagnostics Market Trends and Future Forecast

The Influenza Diagnostics market is set for considerable expansion driven by technological advancements such as digital health solutions, AI-driven diagnostics, and expanded access to rapid testing. Demand for integrated laboratory systems that combine different diagnostics capabilities is also on the rise. By 2033, opportunities for growth will likely be complemented by challenges including regulatory hurdles and market competition. Continuous innovation will be essential in addressing these challenges and maintaining significant growth in the Influenza Diagnostics market over the next decade.

Request a custom research report for industry.

Global Market Leaders and Top Companies in Influenza Diagnostics Industry

Abbott Laboratories:

A leading player known for its rapid molecular diagnostics, Abbott’s innovative systems have revolutionized influenza testing processes.

Roche Diagnostics:

Roche’s advanced diagnostics solutions, focusing on accuracy and reliability, continue to set a high standard in the influenza testing domain.

Cepheid:

Specializing in molecular diagnostics, Cepheid’s revolutionary rapid tests have propelled the company to the forefront of the influenza diagnostics market.

Becton, Dickinson and Company:

BD’s extensive portfolio of diagnostic products and commitment to innovation enables it to address a wide range of influenza diagnostic needs effectively.

Thermo Fisher Scientific:

With a focus on cutting-edge laboratory equipment and diagnostics, Thermo Fisher plays a crucial role in enhancing influenza testing accuracy.

We're grateful to work with incredible clients.

Datasite
Agilent
Asten Johnson
Bio-Rad
Carl Zeiss
Dywidag
Illumina
LEK Consulting
Shell

Related Industries

    FAQs